By–Passing Immunization: Building High Affinity Human Antibodies by Chain Shuffling von Marks, James D., Griffiths, Andrew D., Malmqvist, Magnus, Clackson, Tim P., Bye, Jacqueline M., Winter, Greg

Volltext

Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias von Cortes, Jorge E, Kantarjian, Hagop, Shah, Neil P, Bixby, Dale, Mauro, Michael J, Flinn, Ian, O'Hare, Thomas, Hu, Simin, Narasimhan, Narayana I, Rivera, Victor M, Clackson, Tim, Turner, Christopher D, Haluska, Frank G, Druker, Brian J, Deininger, Michael W.N, Talpaz, Moshe

Volltext

Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients von Garner, Andrew P, Gozgit, Joseph M, Anjum, Rana, Vodala, Sadanand, Schrock, Alexa, Zhou, Tianjun, Serrano, Cesar, Eilers, Grant, Zhu, Meijun, Ketzer, Julia, Wardwell, Scott, Ning, Yaoyu, Song, Youngchul, Kohlmann, Anna, Wang, Frank, Clackson, Tim, Heinrich, Michael C, Fletcher, Jonathan A, Bauer, Sebastian, Rivera, Victor M

Volltext

Phase II Study of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus in Patients With Advanced Bone and Soft Tissue Sarcomas von CHAWLA, Sant P, STADDON, Arthur P, RIVERA, Victor M, CLACKSON, Tim, LOEWY, John W, HALUSKA, Frank G, DEMETRI, George D, BAKER, Laurence H, SCHUETZE, Scott M, TOLCHER, Anthony W, D'AMATO, Gina Z, BLAY, Jean-Yves, MITA, Monica M, SANKHALA, Kamalesh K, BERK, Lori

Volltext

Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients von Deininger, Michael W., Hodgson, J. Graeme, Shah, Neil P., Cortes, Jorge E., Kim, Dong-Wook, Nicolini, Franck E., Talpaz, Moshe, Baccarani, Michele, Müller, Martin C., Li, Jin, Parker, Wendy T., Lustgarten, Stephanie, Clackson, Tim, Haluska, Frank G., Guilhot, Francois, Kantarjian, Hagop M., Soverini, Simona, Hochhaus, Andreas, Hughes, Timothy P., Rivera, Victor M., Branford, Susan

Volltext

Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML von O'Hare, Thomas, Pollock, Roy, Stoffregen, Eric P., Keats, Jeffrey A., Abdullah, Omar M., Moseson, Erika M., Rivera, Victor M., Tang, Hao, Metcalf, Chester A., Bohacek, Regine S., Wang, Yihan, Sundaramoorthi, Raji, Shakespeare, William C., Dalgarno, David, Clackson, Tim, Sawyer, Tomi K., Deininger, Michael W., Druker, Brian J.

Volltext

Long-term pharmacologically regulated expression of erythropoietin in primates following AAV-mediated gene transfer von Rivera, Victor M., Gao, Guang-ping, Grant, Rebecca L., Schnell, Michael A., Zoltick, Philip W., Rozamus, Leonard W., Clackson, Tim, Wilson, James M.

Volltext

Discovery of 3-[2-(Imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a Potent, Orally Active Pan-I... von Huang, Wei-Sheng, Metcalf, Chester A, Sundaramoorthi, Raji, Wang, Yihan, Zou, Dong, Thomas, R. Mathew, Zhu, Xiaotian, Cai, Lisi, Wen, David, Liu, Shuangying, Romero, Jan, Qi, Jiwei, Chen, Ingrid, Banda, Geetha, Lentini, Scott P, Das, Sasmita, Xu, Qihong, Keats, Jeff, Wang, Frank, Wardwell, Scott, Ning, Yaoyu, Snodgrass, Joseph T, Broudy, Marc I, Russian, Karin, Zhou, Tianjun, Commodore, Lois, Narasimhan, Narayana I, Mohemmad, Qurish K, Iuliucci, John, Rivera, Victor M, Dalgarno, David C, Sawyer, Tomi K, Clackson, Tim, Shakespeare, William C

Volltext

Ponatinib in patients with refractory acute myeloid leukaemia: findings from a phase 1 study von Shah, Neil P., Talpaz, Moshe, Deininger, Michael W. N., Mauro, Michael J., Flinn, Ian W., Bixby, Dale, Lustgarten, Stephanie, Gozgit, Joseph M., Clackson, Tim, Turner, Christopher D., Haluska, Frank G., Kantarjian, Hagop, Cortes, Jorge E.

Volltext

Abstract 5655: AP26113 possesses pan-inhibitory activity versus crizotinib-resistant ALK mutants and oncogenic ROS1 fusions von Squillace, Rachel M., Anjum, Rana, Miller, David, Vodala, Sadanand, Moran, Lauren, Wang, Frank, Clackson, Tim, Garner, Andrew P., Rivera, Victor M.

Volltext

Abstract 3394: Ponatinib, a pan-BCR-ABL inhibitor, potently inhibits key activating and drug-resistant KIT mutants found in GIST von Garner, Andrew P., Anjum, Rana, Vodala, Sadanand, Schrock, Alexa, Zhou, Tianjun, Clackson, Tim, Gozgit, Joseph M., Rivera, Victor M.

Volltext

High-Resolution Analysis of the Relationship Between Dose and Molecular Response in CP-CML Patients Treated with Ponatinib or Imatinib von Pritchard, Justin R., Lustgarten, Stephanie, Hodgson, Graeme, Baccarani, Michele, Cortes, Jorge E., Deininger, Michael W., Guilhot, Francois, Hochhaus, Andreas, Hughes, Timothy P., Shah, Neil P., Talpaz, Moshe, Clackson, Tim, Haluska, Frank G., Knickerbocker, Ronald, Rivera, Victor M.

Volltext

Ponatinib Efficacy and Safety in Patients with the T315I Mutation: Long-Term Follow-up of Phase 1 and Phase 2 (PACE) Trials von Mauro, Michael J., Cortes, Jorge E., Hochhaus, Andreas, Baccarani, Michele, Hughes, Timothy P., Guilhot, Francois, Deininger, Michael W., Kantarjian, Hagop M., Shah, Neil P., Bixby, Dale, Flinn, Ian, Lustgarten, Stephanie, Rivera, Victor M., Haluska, Frank G., Clackson, Tim, Talpaz, Moshe

Volltext

Achieving Early Landmark Response Is Predictive of Outcomes in Heavily Pretreated Patients with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Treated with Ponatinib von Mueller, Martin C., Baccarani, Michele, Deininger, Michael W., Guilhot, Francois, Hochhaus, Andreas, Hughes, Timothy P., Shah, Neil P., Talpaz, Moshe, Lustgarten, Stephanie, Rivera, Victor M., Clackson, Tim, Haluska, Frank G., Cortes, Jorge E.

Volltext

Long-Term Follow-up of a Phase 1 Study of Ponatinib in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) von Talpaz, Moshe, Cortes, Jorge E., Kantarjian, Hagop, Shah, Neil P., Bixby, Dale, Flinn, Ian, O’Hare, Thomas, Hu, Simin, Rivera, Victor M., Clackson, Tim, Turner, Christopher D., Haluska, Frank G., Druker, Brian J., Deininger, Michael W., Mauro, Michael J.

Volltext

Longer-term follow up of a phase 1 study of ponatinib in patients (pts) with Philadelphia chromosome-positive (Ph+) leukemias von Talpaz, Moshe, Cortes, Jorge E., Kantarjian, Hagop M., Shah, Neil P., Bixby, Dale L., Flinn, Ian, O'Hare, Thomas, Hu, Simin, Rivera, Victor M., Clackson, Tim, Turner, Christopher D., Haluska, Frank G., Drucker, Brian J, Deininger, Michael W.N., Mauro, Michael J.

Volltext

Epic: A Phase 3 Trial of Ponatinib Compared with Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CP-CML) von Lipton, Jeffrey H., Chuah, Charles, Guerci-Bresler, Agnes, Rosti, Gianantonio, Simpson, David, Assouline, Sarit, Etienne, Gabriel, Nicolini, Franck E., Le Coutre, Philipp, Clark, Richard, Stenke, Leif, Andorsky, David, Oehler, Vivian, Lustgarten, Stephanie, Rivera, Victor M., Clackson, Tim, Haluska, Frank G, Baccarani, Michele, Cortes, Jorge E., Guilhot, Francois, Hochhaus, Andreas, Hughes, Timothy P., Kantarjian, Hagop M., Shah, Neil P., Talpaz, Moshe, Deininger, Michael W.

Volltext

9-(Arenethenyl)purines as Dual Src/Abl Kinase Inhibitors Targeting the Inactive Conformation: Design, Synthesis, and Biological Evaluation von Huang, Wei-Sheng, Zhu, Xiaotian, Wang, Yihan, Azam, Mohammad, Wen, David, Sundaramoorthi, Raji, Thomas, R. Mathew, Liu, Shuangying, Banda, Geetha, Lentini, Scott P, Das, Sasmita, Xu, Qihong, Keats, Jeff, Wang, Frank, Wardwell, Scott, Ning, Yaoyu, Snodgrass, Joseph T, Broudy, Marc I, Russian, Karin, Daley, George Q, Iuliucci, John, Dalgarno, David C, Clackson, Tim, Sawyer, Tomi K, Shakespeare, William C

Volltext

EPIC: A phase III randomized, open-label study of ponatinib versus imatinib in adult patients with newly diagnosed chronic myeloid leukemia in chronic phase von Lipton, Jeffrey H., Deininger, Michael W. N., Lustgarten, Stephanie, Turner, Christopher D., Rivera, Victor M., Clackson, Tim, Baccarani, Michele, Cortes, Jorge E., Guilhot, Francois, Hochhaus, Andreas, Hughes, Timothy P., Kantarjian, Hagop M., Shah, Neil P., Talpaz, Moshe, Haluska, Frank G.

Volltext

EPIC: A phase III trial of ponatinib (PON) versus imatinib (IM) in patients (pts) with newly diagnosed CP-CML von Lipton, Jeffrey Howard, Chuah, Charles, Guerci-Bresler, Agnes, Rosti, Gianantonio, Simpson, David, Lustgarten, Stephanie, Trede, Nikolaus S., Rivera, Victor M., Clackson, Tim, Haluska, Frank G., Baccarani, Michele, Cortes, Jorge E., Guilhot, Francois, Hochhaus, Andreas, Hughes, Timothy P., Kantarjian, Hagop M., Shah, Neil P., Talpaz, Moshe, Deininger, Michael W.N.

Volltext